The RELIANCE Trial provided the first demonstration of licensure-quality CAR-T manufacturing and clinical trial data generation in r/r patients originating in China. These results with relma-cel demonstrate similar preliminary response rates and PK profiles while providing the potential for an improved toxicity profile in heavily-pre-treated patients with r/r DLBCL having poor risk features relative to other CD19-specific CAR-Ts approved in the US and EU.

我们战略性地搭建了差异化的细胞免疫疗法产品管线，涵盖多种提升产品效益风险比的全新一代疗法，包括异基因疗法、联合小分子药物疗法及其他新型基因改造的CAR-T产品。我们相信我们的在研产品有潜力成为各自适应症的突破性疗法。